The PSA Decision Zone: Why Prostate Cancer Assessment Remains a Clinical Challenge

For decades, the PSA (Prostate Specific Antigen) test has been the primary gateway into prostate cancer assessment. It remains one of the most widely used tools available to clinicians, helping identify men who may require further investigation and potentially enabling earlier cancer detection.

Yet despite its widespread adoption, PSA testing continues to present a significant challenge: what happens when the result doesn’t provide a clear answer?

In the latest episode of Pathology News, Dr Asif Naseem, GP and specialist in preventative healthcare and men’s health, alongside Dr Beat Rheiner, CEO of Proteomedix, explore the uncertainty that exists within today’s prostate cancer pathways and why clinicians often find themselves navigating what they describe as the PSA “decision zone”.

An Important Test, But Not a Definitive One

PSA testing plays a vital role in prostate cancer assessment, but it is important to remember that PSA is not a cancer-specific marker.

Elevated PSA levels can be associated with prostate cancer, but they can also be caused by a range of benign conditions, including prostate enlargement, inflammation, infection, and other non-cancerous factors. Equally, some men with clinically significant prostate cancer may have PSA levels that fall below traditional referral thresholds.

This means that while PSA can indicate that further investigation may be warranted, it rarely provides certainty on its own.

As Dr Naseem explains, the test serves as an important entry point into the diagnostic pathway, but the challenge begins when clinicians are required to determine what should happen next.

Moving Beyond the “Grey Zone”

A key point of discussion was the commonly used term “PSA grey zone” and whether it truly reflects the clinical reality.

The PSA ‘grey zone’ traditionally refers to results between 4 and 10 ng/mL, but as the discussion highlights, clinically significant prostate cancers are also frequently found in men with PSA levels between 2 and 4 ng/mL. The real challenge, then, isn’t confined to a specific number on a test. It’s about making informed decisions when PSA alone can’t give you the full picture.

Rather than describing this area as a lack of knowledge, both speakers suggested that the real issue is one of decision-making.

Patients with PSA values that sit within intermediate ranges often represent the most challenging cases. Clinicians may have enough information to know that a patient deserves closer attention, but insufficient evidence to confidently determine the most appropriate next step.

For Dr Rheiner, this is better described as a “decision zone” rather than a “grey zone”.

The distinction is important. The problem is not that clinicians lack information altogether. Instead, they are often working with incomplete information that makes risk assessment and patient triage more difficult.

The Burden of Uncertainty

This uncertainty affects both clinicians and patients.

From a GP’s perspective, PSA results rarely exist in isolation. Decisions are influenced by multiple factors, including age, symptoms, family history, genetic risk factors, physical examination findings, and previous test results.

Even with this additional context, determining which patients should be referred for MRI, biopsy, or specialist assessment can be challenging.

Dr Naseem spoke about the realities of these conversations, acknowledging that even clinicians with a particular interest in prostate cancer can encounter cases that defy expectations.

For patients, the experience can be equally difficult.

Many men undergo PSA testing expecting a straightforward answer. Instead, they may receive a result that raises questions without providing clear direction. Some have no symptoms at all, making an elevated PSA particularly difficult to interpret and often a source of significant anxiety.

A Pathway Built Around Decisions

Importantly, the discussion did not suggest that current prostate cancer pathways are failing.

Modern diagnostic pathways involving MRI imaging, biopsy, specialist review, and treatment planning continue to identify clinically significant cancers and improve patient outcomes.

The challenge lies earlier in the pathway.

As Dr Naseem explained, the issue is not necessarily the downstream investigations but rather how patients are filtered into those pathways in the first place. Clinicians need to make decisions with imperfect information, balancing the risk of missing significant disease against the consequences of unnecessary investigations.

This is where the PSA decision zone becomes most apparent.

Looking Ahead

As prostate cancer awareness continues to increase, more men are seeking PSA testing and engaging in conversations about their risk.

While PSA remains an invaluable tool, the podcast highlights an important reality: the greatest challenge is often not identifying patients who may be at risk but determining what action should follow.

Understanding and addressing this decision zone may prove to be one of the most important opportunities for improving prostate cancer pathways in the years ahead.

In Episode 2, we continue the conversation by exploring smarter triage approaches and how they may help clinicians make more informed decisions in everyday practice.